What percentage of children aged 6 to under 12 no longer had obesity after 68 weeks of semaglutide treatment in the STEP Young trial?

According to the news, '40.4% of children aged 6 to under 12 treated with semaglutide [...] were no longer classified as having obesity after 68 weeks, assuming full adherence to the treatment.'

What was the primary endpoint outcome of the STEP Young trial for semaglutide?

The trial met its primary endpoint by demonstrating 'superior body mass index reduction at week 68 in the group taking once-weekly subcutaneous semaglutide compared with the placebo group.'

Novo Nordisk Says Semaglutide Reduced Obesity Rates in Young Children in Trial

Sep 7, 2026

Novo Nordisk reported that 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks in the STEP Young trial. Safety profiles remained consistent with adult data while showing superior BMI reduction versus placebo.

reuters

2026-09-07

Novo Nordisk Says Semaglutide Reduced Obesity Rates in Young Children in Trial

2026-09-07

Novo scraps two more heart drug trials, further dimming growth beyond obesity

2026-09-07

Stocks in Asia Poised to Edge Down, Yen in Focus: Markets Wrap

Novo Nordisk Says Semaglutide Reduced Obesity Rates in Young Children in Trial

FAQ